<HTML>
<HEAD>
<TITLE>CATALYST PHARMACEUTICAL PARTNERS, INC.</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Registration No.&nbsp;333-</B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</DIV>


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt; margin-top: 3pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM S-8</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>REGISTRATION STATEMENT<BR>
UNDER<BR>
THE SECURITIES ACT OF 1933</B>
</DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>Catalyst Pharmaceutical Partners, Inc.</B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>76-0837053</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or Other Jurisdiction of <BR>
Incorporation or Organization)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(I.R.S. Employer Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>355 Alhambra Circle<BR>
Suite&nbsp;1370<BR>
Coral Gables, Florida 33134</B><BR>
(Address of Principal Executive Offices)<BR>
(Zip Code)</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Patrick J. McEnany Non-Qualified Stock Option Agreements<BR>
Hubert E. Huckel Non-Qualified Stock Option Agreements<BR>
Jack Weinstein Non-Qualified Stock Option Agreements<BR>
M. Douglas Winship Stock Option Agreement<BR>
Charles B. O&#146;Keeffe Non-Qualified Stock Option Agreement<BR>
Donald R. Jasinski Consulting Agreement</B><BR>
(Full Titles of the Plans)</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Patrick J. McEnany<BR>
355 Alhambra Circle, Suite&nbsp;1370<BR>
Coral Gables, Florida 33134</B><BR>
(Name and Address of Agent for Service)</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>With a copy to:</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Philip B. Schwartz, Esq.<BR>
Akerman Senterfitt<BR>
One Southeast Third Avenue, 25</B><SUP style="font-size: 85%; vertical-align: text-top"><B>th</B></SUP><B> Floor<BR>
Miami, Florida 33131<BR>
(305)&nbsp;374-5600</B></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act. (Check one):</DIV>
<TABLE width="100%" style="font-size: 10pt; margin-top: 0pt"><TR><TD>Large accelerated filer&nbsp;<FONT face="Wingdings">&#111;</FONT></TD><TD align="center">Accelerated filer&nbsp;<FONT face="Wingdings">&#111;</FONT>&nbsp;</TD><TD align="center">Non-accelerated filer&nbsp;<FONT face="Wingdings">&#111;</FONT><BR>(Do not check if a smaller reporting company)</TD><TD align="right">Smaller reporting company&nbsp;<FONT face="Wingdings">&#120;</FONT></TD></TR></TABLE>



</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>CALCULATION OF REGISTRATION FEE</B></DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="54%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD><!-- VRule -->
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD><!-- VRule -->
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD><!-- VRule -->
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD><!-- VRule -->
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>

    <TD width="1%">&nbsp;</TD>
</TR><TR style="font-size: 1px" valign="bottom">
    <TD nowrap align="left" colspan="23" style="border-bottom: 3px double #000000">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">    <TD width="1%">&nbsp;</TD>

    <TD nowrap align="center"><B>Title of Each Class</B></TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Proposed Maximum</B></TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Proposed Maximum</B></TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">    <TD width="1%">&nbsp;</TD>

    <TD nowrap align="center"><B>of Securities to be</B></TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Amount to be</B></TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Offering Price Per</B></TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Aggregate Offering</B></TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Amount of</B></TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">    <TD width="1%">&nbsp;</TD>

    <TD nowrap align="center"><B>Registered</B></TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Registered (1)</B></TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Share (2)</B></TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Price</B></TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Registration Fee</B></TD>
    <TD width="1%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD width="1%" style="border-top: 1px solid #000000">&nbsp;</TD>
                    <TD style="border-top: 1px solid #000000"><DIV style="margin-left:15px; text-indent:-15px">Common Stock</DIV></TD>
    <TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
    <TD style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">2,352,254</TD>
    <TD style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
    <TD style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">$</TD>
    <TD align="right" style="border-top: 1px solid #000000">3.59</TD>
    <TD style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
    <TD style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">$</TD>
    <TD align="right" style="border-top: 1px solid #000000">8,445,000</TD>
    <TD style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
    <TD style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">$</TD>
    <TD align="right" style="border-top: 1px solid #000000">331.89</TD>
    <TD style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD width="1%" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px" valign="bottom">
    <TD nowrap align="left" colspan="23" style="border-top: 3px double #000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 6pt; width: 18%; border-top: 0px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">(1)</TD>
    <TD>&nbsp;</TD>
    <TD>Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;),
this Registration Statement on Form S-8 also covers an indeterminate number of additional shares of
common stock that may become issuable in the future under the various stock option plans as a
result of stock splits, stock dividends or other similar transactions.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(2)</TD>
    <TD>&nbsp;</TD>
    <TD>Estimated solely for the purpose of computing the registration fee. This amount was calculated
pursuant to Rule 457(h) under the Securities Act on the basis of $3.59 per share, which was the
average of the high and low sale prices of the Registrant&#146;s common stock on the Nasdaq Global
Market on May&nbsp;30, 2008.</TD>
</TR>

</TABLE>



<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>







<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</div>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">








<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXPLANATORY NOTE</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Catalyst Pharmaceutical Partners, Inc. (the &#147;Registrant&#148; or the &#147;Company&#148;) has prepared this
Registration Statement in accordance with the requirements of Form S-8 under the Securities Act of
1933 to register an aggregate of 2,352,254 shares of its common stock, par value $0.001 per share,
issuable upon the exercise of stock options granted to some of its
directors, employees, officers
and scientific advisors. This Registration Statement also includes a reoffer prospectus. Certain
shares offered by the reoffer prospectus are &#147;control securities&#148; (as defined in General
Instruction C to Form S-8). The other shares covered by the reoffer prospectus are &#147;restricted
securities&#148; (as defined in General Instruction C to Form S-8)
</DIV>

<!-- link1 "PART I" -->

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PART I</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Information required by Item&nbsp;1 to be contained in the Section 10(a) prospectus is omitted from this
Registration Statement in accordance with Rule&nbsp;428 under the Securities Act and the Note to Part&nbsp;I
of Form S-8. This information will be sent or given to all persons with whom we have stock option
agreements as specified by Rule&nbsp;428(b)(1) of the Securities Act. This information and the
documents incorporated by reference in this Registration Statement pursuant to Item&nbsp;3 of Part&nbsp;II of
this Registration Statement, constitute a prospectus that meets the requirements of Section 10(a)
of the Securities Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The reoffer prospectus referred to in the Explanatory Note follows this page.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>2,352,254 Shares</B>
</DIV>


<DIV align="Center" style="font-size: 12pt; margin-top: 6pt"><B>CATALYST PHARMACEUTICAL PARTNERS, INC.</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>COMMON STOCK</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus relates to 2,352,254 shares of our common stock that may be offered and resold
from time to time by the selling stockholders identified in this reoffer prospectus for their own
accounts. The shares offered in this prospectus were issued pursuant to various stock option
agreements with the selling stockholders. All of the selling stockholders are directors, officers,
employees or scientific advisors to and of our company. We will receive no part of the proceeds
from sales made under this prospectus.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The shares of common stock covered by this prospectus are &#147;restricted securities&#148; and, in some
cases, &#147;control securities&#148; under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;).
This prospectus has been prepared to allow for future resales of the shares covered by this
prospectus by the selling stockholders, on a continuous or delayed basis, to the public. The number
of shares that each selling stockholder may sell is set forth under Rule 144(e) under the
Securities Act. Each stockholder that resells shares of our common stock pursuant to this
prospectus may be deemed an &#147;underwriter&#148; within the meaning of the Securities Act. Any commissions
received by a broker or dealer in connection with resales of shares of our commons tock covered by
this prospectus may be deemed to be underwriting commissions or discounts under the Securities Act.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The selling stockholders, or their pledgees, donees, transferees or other
successors-in-interest, may resell their shares of common stock covered by this prospectus from
time to time in one or more public or private transactions at prevailing market prices, at prices
related to prevailing market prices or at privately negotiated prices.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are paying the expenses incurred in registering the shares covered by this prospectus and
the preparation of this prospectus, but all selling and other expenses, including but not limited
to any discounts, commissions and applicable transfer taxes, incurred by each of the selling
stockholders will be borne by such stockholder.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock is listed on the Nasdaq Global Market under the symbol &#147;CPRX&#148;. On May&nbsp;30, 2008,
2008, the last reported sale price of our common stock was $3.59 per share.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our principal executive officers are located at 355 Alhambra Circle, Suite&nbsp;1370, Coral Gables,
Florida 33134. Our telephone number is (305)&nbsp;529-2522.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>INVESTING IN OUR COMMON STOCK INVOLVES RISKS. SEE &#147;</B><U><B>RISK FACTORS</B></U><B>&#148; ON PAGE 6 OF THIS
PROSPECTUS FOR A DISCUSSION OF THOSE RISKS.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS
APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR
COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">The date of this reoffer prospectus is June 2, 2008.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left">
<!-- TOC -->
</DIV>
<DIV align="left">
<A name="tocpage"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#101">Available Information</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#102">Incorporated Documents</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#103">Certain Definitions</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#104">The Company</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#105">Risk Factors</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#106">Special Note Regarding Forward-Looking Statements</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#107">Use of Proceeds</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#108">Dividend Policy</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#109">Selling
Stockholders</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#110">Plan of Distribution</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#111">Disclosure of SEC&#146;s Position on Indemnification for Securities Act Liabilities</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#112">Legal Matters</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#113">Experts</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g13728exv5w1.htm">EX-5.1 OPINION of AKERMAN SENTERFITT LLP</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g13728exv23w2.htm">EX-23.2 CONSENT OF GRANT THORNTON LLP.</A></FONT></TD></TR>
</TABLE>
</DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>You should rely only on the information included or incorporated by reference in this
prospectus. We have not authorized anyone else to provide you with different information. If anyone
provides you with different or inconsistent information, you should not rely on it. The shares of
common stock covered by this prospectus are not being offered or sold in any jurisdiction where
such offer or sale is not permitted. You should not assume that the information included or
incorporated by reference in this prospectus is accurate as of any date other than the date on the
front cover of this prospectus. Our business, financial condition, results of operations and
prospects may have changed since that date.</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left">
<A name="101"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AVAILABLE INFORMATION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are subject to the informational reporting requirements of the Securities Exchange Act of
1934, as amended (the &#147;Exchange Act&#148;), and file reports, proxy statements and other information
with the Securities and Exchange Commission (the &#147;SEC&#148;). You may read and copy any document that we
file at the SEC&#146;s Public Reference Room, which is located at 100 F Street, NE, Washington, DC
20549. Please call 1-800-SEC-0330 for further information on the SEC&#146;s Public Reference Room. Our
SEC filings are also available to the public at the SEC&#146;s
website at <U>http://www.sec.gov</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also make available on our website, <U>http://www.catalystpharma.com</U>, free of charge, the
documents we file with the SEC, as soon as is practicable after we file documents with the SEC.
Information on or connected to our web site shall not be deemed to be a part of this prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have filed with the SEC hereunder a Registration Statement on Form S-8 under the Securities
Act covering the shares of our common stock to be resold from time to time under this prospectus by
certain selling stockholders covered by this prospectus pursuant to the various stock option
agreements and their pledgees, donees, transferees or other successors in interest. The SEC permits
us to omit from this prospectus certain information, exhibits and undertakings contained in the
Registration Statement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You should rely only on the information incorporated by reference or provided in this
prospectus or a prospectus supplement accompanying this prospectus. We have not authorized anyone
to provide you with different information. If anyone provides you with different or inconsistent
information, you should not rely on it. The shares of common stock covered by this prospectus are
not being offered or sold in any jurisdiction where the offer or sale is not permitted. You should
not assume that the information in this prospectus is accurate as of any date other than the date
on the front of this prospectus, since our business, financial condition, results of operations
and prospects may have changed since that date.
</DIV>
<DIV align="left">
<A name="102"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>INCORPORATED DOCUMENTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC allows us to &#147;incorporate by reference&#148; information into this prospectus, which means
that we can disclose important information to you by referring you to another document filed
separately with the SEC. The information incorporated by reference is deemed to be a part of this
prospectus, except for any information superseded by information in this prospectus or by any
information in a prospectus supplement accompanying this prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following documents filed with the SEC are incorporated by reference in this prospectus:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Our Annual Report on Form 10-K for the year ended December&nbsp;31, 2007, filed with the SEC
on March&nbsp;25, 2008;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Our Proxy Statement for the 2008 Annual Meeting of Stockholders to be held on June&nbsp;18,
2008, filed with the SEC on April&nbsp;29, 2008;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Our Quarterly Report on Form 10-Q for the three months ended March&nbsp;31, 2008, filed with
the SEC on May&nbsp;15, 2008; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Our description of our common stock contained in our Registration Statement on Form
8-A, filed with the SEC on September&nbsp;29, 2006, along with Amendment No.&nbsp;1 thereto, filed
with the SEC on October&nbsp;18, 2006.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Registration Statement on Form S-8 also incorporates by reference all documents
subsequently filed by the Company pursuant to Sections&nbsp;13(a), 13(c), 14 and 15(d) of the Exchange
Act, from the date of filing of such documents, before the filing of a post-effective amendment to
this Registration Statement which indicates that all securities offered hereunder have been sold or
which deregisters all securities then remaining unsold.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You may obtain a copy of any of these documents at no cost by requesting them from us or by
writing or calling: Catalyst Pharmaceutical Partners, Inc., 355 Alhambra Circle, Suite&nbsp;1370, Coral
Gables, Florida, 33134, Attn: Investor Relations, or by calling (305)&nbsp;529-2522.
</DIV>
<DIV align="left">
<A name="103"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CERTAIN DEFINITIONS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except where the context suggests otherwise, &#147;we&#148;, &#147;us&#148;, &#147;our&#148;, and &#147;the Company&#148; refer to
Catalyst Pharmaceutical Partners, Inc.
</DIV>
<DIV align="left">
<A name="104"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>THE COMPANY</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a development-stage biopharmaceutical company focused on the acquisition, development
and commercialization of prescription drugs for the treatment of drug addiction and obsessive
compulsive disorders. Our initial product candidate is CPP-109, which is our version of vigabatrin.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The successful development of CPP-109 or any other product we may develop, acquire, or license
is highly uncertain. We cannot reasonably estimate or know the nature, timing, or estimated
expenses of the efforts necessary to complete the development of, or the period in which material
net cash inflows are expected to commence due to the numerous risks and uncertainties associated
with developing, such products, including the uncertainty of:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the scope, rate of progress and expense of our clinical trials and our other product
development activities;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the results of future clinical trials, and the number of clinical trials (and the
scope of such trials) that will be required to seek and obtain approval of a new drug
application, or NDA, for CPP-109; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the expense of filing, prosecuting, defending and enforcing any patent claims and
other intellectual property rights.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our principal executive offices are located at 355 Alhambra Circle, Suite&nbsp;1370, Coral Gables,
Florida 33134. Our telephone number is (305)&nbsp;529-2522. Our website is
<U>http://www.catalystpharma.com</U>. The information contained in, or that can be accessed
through, our website is not a part of this prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Recent Developments</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>U.S. Phase II clinical trial for cocaine addiction</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During July&nbsp;2007, we initiated a randomized, double-blind, placebo-controlled U.S. Phase II
clinical trial evaluating the use of CPP-109 in treating patients with cocaine addiction. We estimate that the cost of this trial will be approximately $6,000,000.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The trial is expected to enroll 180 cocaine addicted patients at not less than 11 addiction
treatment clinical centers in the United States. Patients will be treated for a period of 12&nbsp;weeks,
with an additional 12&nbsp;weeks of follow-up. The primary endpoint of the trial is to demonstrate that
a larger proportion of CPP-109-treated subjects than placebo-treated subjects will be cocaine-free
during their last two weeks of treatment (weeks 11 and 12). Additionally, we will be measuring
several secondary endpoints based on reductions of cocaine use and craving. To be eligible to
participate in this trial, participants must meet specific clinical standards for cocaine
dependence, as specified in DSM-IV, a set of diagnosis guidelines established for clinical
professionals. Additionally, trial participants cannot meet the DSM-IV criteria for dependence on
most other addictive substances. Further, eye safety studies will be conducted on all trial
participants before and after the trial to determine the extent of visual field defects that may
occur as a result of the trial among such participants, if any. We began enrolling patients in our
trial in January&nbsp;2008 after the protocol for our trial was accepted by the U.S. Food and Drug
Administration (&#147;FDA&#148;). Based on currently available information, we expect to have initial
top-line results from this trial in the fourth quarter of 2008. However, the date we obtain the
results from our study will ultimately depend on the timing of patient enrollment into our study,
which cannot be predicted with absolute certainty. Additional information about our trial can be
found at<U> www.clinicaltrials.gov</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>U.S. Phase II clinical trial for methamphetamine addiction</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect to initiate during the second quarter of 2008 a 180 patient randomized, double-blind, placebo-controlled U.S.
Phase II clinical trial evaluating the use of CPP-109 in treating patients with methamphetamine
addiction. This trial will be similar to our cocaine trial. We currently estimate that the cost of this trial will
be approximately $5,900,000. Based on currently available information, we expect to have initial
top-line results from this trial during the third quarter of 2009.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Contemplated pilot clinical trials</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We hope to initiate during 2008 a Phase II clinical trial evaluating CPP-109 for the treatment
of binge eating disorder or BED. BED, which impacts a subset of the obese population, affects
approximately four million people in the United States. We are also contemplating and hope to
launch during 2008 additional Phase II proof-of-concept trials evaluating the use of CPP-109 for
the treatment of other addictions, including alcohol and nicotine.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Discussions with strategic partners</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have had in the past, and expect to continue to have in the future, discussions with potential strategic partners interested in working with
us on the development of CPP-109. No agreements have been entered into to date with
any potential strategic partners.
</DIV>
<DIV align="left">
<A name="105"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>RISK FACTORS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Before making an investment decision, you should carefully consider the risks described under
&#147;Risk Factors&#148; in the applicable prospectus supplement and in our most recent Annual Report on Form
10-K, or any updates in subsequent Quarterly Reports on Form 10-Q, together with all of the other
information appearing in this prospectus or incorporated in this prospectus by reference and any
applicable prospectus supplement, in light of your particular investment objectives.
</DIV>
<DIV align="left">
<A name="106"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some of the statements provided in or incorporated by reference by this prospectus contain
&#147;forward-looking statements,&#148; including statements regarding our expectations, beliefs, plans or
objectives for future operations and anticipated results of operations. For this purpose, any
statements contained herein that are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the foregoing, the words, &#147;believes,&#148; &#147;anticipates,&#148;
&#147;proposes,&#148; &#147;plans,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;may&#148; and similar expressions are intended to identify
forward-looking statements. Such statements involve known and unknown risks, uncertainties and
other factors that may cause our actual results, performance or achievements to be materially
different from any future results, performance or achievements expressed or implied by such
forward-looking statements. The forward-looking statements made in this prospectus are based on
current expectations that involve numerous risks and uncertainties, including but not limited to
the following:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our having sufficient financial resources;</TD>
</TR>

</TABLE>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our ability to successfully complete our clinical and non-clinical trials required for us to file and obtain
approval of a NDA for our product candidate CPP-109;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our ability to complete such trials on a timely basis and within the budgets we establish
for such trials;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our ability to protect our intellectual property;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>whether others develop and commercialize products competitive to our products;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>changes in the regulations affecting our business;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our ability to attract and retain skilled employees; and</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>changes in general economic conditions and interest rates.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our current plans and objectives are based on assumptions relating to the development of our
business. Although we believe that our assumptions are reasonable, any of our assumptions could
prove inaccurate. In light of the significant uncertainties inherent in the forward-looking
statements made herein, which reflect our views only as of the date of this prospectus, you should
not place undue reliance upon such statements. We undertake no obligation to update or revise
publicly any forward-looking statements, whether as a result of new information, future events or
otherwise.
</DIV>
<DIV align="left">
<A name="107"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>USE OF PROCEEDS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will not receive any of the proceeds from the resale of the shares of our common stock
covered by this prospectus. We will pay all costs and expenses incurred by us in connection with
the registration under the Securities Act of the shares of our common stock covered by this
prospectus.
</DIV>

<DIV align="left">
<A name="108"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>DIVIDEND POLICY</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not anticipate that we will pay any cash dividend on our common stock in the foreseeable
future. We intend to retain all available funds and any future earnings to fund the development and
growth of our business.
</DIV>

<DIV align="left">
<A name="109"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SELLING STOCKHOLDERS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus permits the resale of up to 2,352,254 shares of common stock by the selling
stockholders identified below and their pledgees, donees, transferees and other successors in
interest that receive shares from a selling stockholder as a gift, distribution or other non
sale-related transfer after the date of this prospectus (all of whom may be selling stockholders
for purposes of this prospectus). The shares of common stock covered by this prospectus may be
offered and resold when and as the selling stockholders deem appropriate. All of the selling
stockholders are directors, officers, employees or advisors of or scientific advisors to our
company. The selling stockholders acquired these shares from us pursuant to awards or stock option
grants under individual stock option agreements. The shares of common stock covered by this
prospectus may not be sold or otherwise transferred by the selling stockholders named in the table
below unless and until the restrictions on sales or other transfers applicable to the shares of
common stock acquired under such agreements lapse in accordance with the terms and conditions of
such agreements and any applicable grant instrument.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth: (i)&nbsp;the name of each selling stockholder; (ii)&nbsp;any position,
office or other material relationships with our company, over the last three years of each selling
stockholder; (iii)&nbsp;the number and percentage of shares of our common stock, known to us, that each
selling stockholder beneficially owned prior to the offering for resale of the shares under this
prospectus; (iv)&nbsp;the number of shares of common stock that may be offered for resale for the
account of each selling stockholder under this prospectus; and (v)&nbsp;the number and percentage of
shares of common stock to be beneficially owned by each selling stockholder after the offering of
the shares under this prospectus (assuming all of the shares under this prospectus are sold for the
account of each selling stockholder and no other shares of common stock are acquired or sold by
each selling stockholder).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The number of shares in the column &#147;Number of Shares Being Offered&#148; represents all of the
shares of common stock that each selling stockholder may offer under this prospectus. We do not
know
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">how long the selling stockholders will hold these shares before selling them or how many shares
they will sell. We currently have no agreements, arrangements or understandings with any of the
selling stockholders regarding the sale of any of the shares covered by this prospectus. The
shares of common stock offered by this prospectus may be offered from time to time by the selling
stockholders listed below as described in this prospectus under the heading &#147;Plan of Distribution.&#148;
We cannot assure you that any of the selling stockholders listed below will offer or resell any or
all of the shares of common stock offered by them by this prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless indicated otherwise in the notes to the table below, each selling stockholder has sole
voting and sole investment power over the shares of common stock beneficially owned by each selling
stockholder, and the address of each selling stockholder is c/o Catalyst Pharmaceutical Partners,
Inc., 355 Alhambra Circle, Suite&nbsp;1370, Coral Gables, Florida 33134.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Number of Shares</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">Shares Beneficially Owned</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Beneficially Owned</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Number of Shares</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000">After Offering (2)</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Name</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">Prior to Offering (1)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">Being Offered (2)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Number</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Percentage</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Huckel, Hubert (3)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,913,742</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">729,608</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,184,134</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6.9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Jasinski, Donald (4)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17,510</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17,510</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">*</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">McEnany, Patrick (5)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,975,894</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">729,608</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,246,286</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19.0</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">O&#146;Keeffe, Charles (6)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">360,619</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">291,843</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">68,776</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">*</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Weinstein, Jack (7)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">443,761</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">437,764</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,997</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">*</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Winship, M. Douglas (8)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">145,921</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">145,921</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">*</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">*</TD>
    <TD>&nbsp;</TD>
    <TD>Less than one percent</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(1)</TD>
    <TD>&nbsp;</TD>
    <TD>Beneficial ownership has been determined in accordance with Rule&nbsp;13d-3 under the Exchange Act.
A person is deemed to be the beneficial owner of shares of common stock if that person has or
shares voting power or investment power with respect to those shares or has the right to acquire
beneficial ownership of those shares within 60&nbsp;days of June 2008.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(2)</TD>
    <TD>&nbsp;</TD>
    <TD>Assumes that all shares of common stock to be offered are sold pursuant to this offering and
that no other shares of common stock are acquired or disposed of by the selling stockholders prior
to the termination of this offering. Because the selling stockholders or their pledgees, donees,
transferees, or other successors in interest may sell all, some or none of the shares of common
stock covered by this prospectus or may acquire or dispose of other shares of our common stock, no
reliable estimate can be made of the aggregate number of shares of common stock that will be sold
pursuant to this offering. The percentage of shares beneficially owned by each selling stockholder
after this offering is based on the 12,567,226 shares of common stock outstanding as of April&nbsp;29,
2008.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(3)</TD>
    <TD>&nbsp;</TD>
    <TD>Dr.&nbsp;Huckel serves as a director of the Company</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(4)</TD>
    <TD>&nbsp;</TD>
    <TD>Dr.&nbsp;Jasinski is a consultant to the Company and serves on the Company&#146;s Scientific Advisory
Board.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(5)</TD>
    <TD>&nbsp;</TD>
    <TD>Mr.&nbsp;McEnany serves as Chairman of the Board, President and Chief Executive Officer of the
Company.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(6)</TD>
    <TD>&nbsp;</TD>
    <TD>Mr.&nbsp;O&#146;Keeffe is a Consultant to the Company and serves on the Company&#146;s Board of Directors.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(7)</TD>
    <TD>&nbsp;</TD>
    <TD>Mr.&nbsp;Weinstein serves as a Vice President, Treasurer and Chief Financial Officer of the Company</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(8)</TD>
    <TD>&nbsp;</TD>
    <TD>Mr.&nbsp;Winship serves as the Company&#146;s Vice President of Regulatory Operations.</TD>
</TR>

</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">





<DIV align="left">
<A name="110"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PLAN OF DISTRIBUTION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The purpose of this prospectus is to permit each selling stockholder and his or her pledgees,
donees, transferees and other successors in interest (all of whom may be selling stockholders for
purposes of this prospectus) to offer and resell all or a portion of the shares the selling
stockholders have acquired pursuant to the stock option agreements. The selling stockholders may
also choose to dispose of all or a portion of the shares of common stock covered by this prospectus
by gift to a third party or as a donation to a charitable or other nonprofit entity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The sale of the common stock by any selling stockholder, including any donee, pledgee or other
transferee who receives common stock from a selling stockholder, may be effected from time to time
by selling shares directly to purchasers or to or through broker-dealers. In connection with any
such sale, any such broker dealer may act as agent for the selling stockholder or may purchase from
the selling stockholder all or a portion of the common stock as principal, and sales may be made
pursuant to any of the methods described below. These sales may be made on any securities exchange
on which our common stock is then traded, in the over-the-counter market, in negotiated
transactions or otherwise at prices and at terms then prevailing or at prices related to the then
current market prices or at prices otherwise negotiated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The common stock may also be sold in one or more of the following transactions:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>block transactions (which may involve crosses) in which a broker dealer may sell all or a
portion of such securities as agent but may position and resell all or a portion of the block
as principal to facilitate the transaction;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>purchases by a broker dealer, as principal, and resale by such broker dealer for its own
account pursuant to a prospectus supplement;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>a special offering, an exchange distribution or a secondary distribution in accordance with
applicable rules promulgated by the National Association of Securities Dealers, or stock
exchange rules;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>ordinary brokerage transactions and transactions in which a broker dealer solicits
purchasers;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>sales &#147;at the market&#148; to or through a market maker or into an existing trading market, on
an exchange or otherwise, for such securities; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>sales in other ways not involving market markers or established trading markets, including
direct sales to purchasers.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In effecting sales, broker-dealers engaged by a selling stockholder may arrange for other
broker-dealers to participate. Broker-dealers may receive commissions or other compensation from
the selling stockholder in the form of commissions, discounts or concessions. Broker-dealers may
also receive compensation from purchasers of the common stock for whom they act as agents or to
whom they sell as principals or both. Compensation as to a particular broker dealer will be in
amounts to be negotiated. The selling stockholders do not expect these commissions and discounts to
exceed what is customary in the type of transactions involved. No such broker dealer will receive
compensation in excess of that permitted by the rules of the Financial Industry Regulatory
Authority, or FINRA. In no event will any broker dealer receive total compensation in excess of the
maximum amount allowed by FINRA.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The distribution of the common stock covered by this prospectus also may be effected from time
to time in one or more underwritten transactions at a fixed price or prices that may be changed, or
at
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">market prices prevailing at the time of sale, at prices related to such prevailing market prices or
at negotiated prices. Any such underwritten offering may be on a &#147;best efforts&#148; or a &#147;firm
commitment&#148; basis. In connection with any underwritten offering, underwriters or agents may receive
compensation in the form of discounts, concessions or commissions from the selling stockholders or
from purchasers of the common stock. Underwriters may sell the common stock to or through dealers,
and such dealers may receive compensation in the form of discounts, concessions or commissions from
the underwriters and/or commissions from the purchasers for whom they may act as agents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The selling stockholders have advised us that they have not entered into any agreements,
understandings or arrangements with any underwriters or broker-dealers regarding the sale of their
common stock covered by this prospectus, nor is there any underwriter or coordinating broker dealer
acting in connection with the proposed sale of common stock by the selling stockholders pursuant to
this prospectus. We will file a supplement to this prospectus, if required, under Rule 424(b) under
the Securities Act that will include any material information with respect to the plan of
distribution not previously disclosed or any material change in such information. This supplement
will disclose, among other information:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the names of the selling stockholders and of participating broker dealer(s);</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the amount of common stock involved;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the price at which the common stock is to be sold;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the commissions paid or the discounts or concessions allowed to the broker dealer(s), where
applicable;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>that the broker dealer(s) did not conduct any investigation to verify the information set
out or incorporated by reference in the prospectus; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>other facts material to the transaction.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The selling stockholders and any underwriters, or broker-dealers or agents that participate in
the distribution of the common stock covered by this prospectus may be deemed to be &#147;underwriters&#148;
within the meaning of Section&nbsp;2(a)(11) of the Securities Act, and any profit on the sale of the
common stock by them and any discounts, commissions or concessions received by any such
underwriters, dealers or agents may be deemed to be underwriting discounts and commissions under
the Securities Act. Because the selling stockholders may be deemed to be &#147;underwriters&#148; under the
Securities Act, the selling stockholders will be subject to the prospectus delivery requirements of
the Securities Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will not receive any of the proceeds from the sale of the shares covered by this
prospectus. We are paying the expenses incurred in registering the shares of common stock covered
by this prospectus and preparing this prospectus, but all selling and other expenses, including but
not limited to any discounts, commissions and applicable transfer taxes, incurred by each selling
stockholder will be borne by that selling stockholders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The selling stockholders may agree to indemnify any agent, dealer or broker dealer that
participates in a transaction involving the sale of shares of common stock covered by this
prospectus against certain liabilities, including liabilities arising under the Securities Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From time to time, the selling stockholders may pledge their common stock pursuant to the
margin provisions of their customer agreements with their brokers. Upon default by a selling
stockholder,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the broker may offer and sell such pledged common stock from time to time. Upon a sale of the
common stock, the selling stockholders intend to comply with the prospectus delivery requirements
under the Securities Act by delivering a prospectus to each purchaser in the transaction. We intend
to file any amendments or other necessary documents in compliance with the Securities Act that may
be required in the event the selling stockholders default under any customer agreement with
brokers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have informed the selling stockholders that the anti manipulative provisions of Regulation
M promulgated under the Exchange Act, may apply to their sales in the market.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to comply with the securities laws of certain states, if applicable, the common stock
covered by this prospectus may be sold only through registered or licensed broker-dealers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The selling stockholders may resell all or a portion of the shares of common stock covered by
this prospectus in open market transactions in reliance upon Rule&nbsp;144 (as in effect at the time of
sale) under the Securities Act, provided they meet the criteria and conform to the requirements of
such rule. In addition, in accordance with General Instruction C to Form S-8, shares of common
stock to be offered or resold by means of this prospectus by a selling stockholder may not exceed,
during any three month period, the amount specified in Rule 144(e) under the Securities Act.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<A name="111"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>DISCLOSURE OF SEC&#146;S POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insofar as indemnification for liabilities arising under the Securities Act of 1933, as
amended, may be permitted as to our officers, directors, or persons controlling us, we have been
advised that it is the SEC&#146;s opinion that such indemnification is against public policy as
expressed in the Securities Act of 1933, as amended, and is therefore unenforceable.
</DIV>
<DIV align="left">
<A name="112"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>LEGAL MATTERS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The validity of shares of common stock offered by the selling shareholders named in this
prospectus will be passed upon for us by Akerman Senterfitt, Miami, Florida.
</DIV>
<DIV align="left">
<A name="113"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXPERTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The financial statements contained in the Annual Report on Form 10-K for the year ended
December&nbsp;31, 2007 incorporated by reference in this Prospectus have been audited by Grant Thornton
LLP, independent registered public accountants, as indicated in their report with respect thereto,
and is included herein in reliance upon the authority of said firm as experts in accounting and
auditing in giving said report.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- TOC -->
<!-- /TOC -->



<!-- link1 "PART II" -->

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PART II</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</B>

</DIV>
<!-- link2 "Item&nbsp;3. Incorporation of Documents by Reference." -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;3. Incorporation of Documents by Reference.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The following documents filed with the Securities and Exchange Commission (the &#147;Commission&#148;) by
Catalyst Pharmaceutical Partners, Inc. (the &#147;Company&#148;) pursuant to the Securities Exchange Act of
1934, as amended (the &#147;Exchange Act&#148;), are incorporated by reference in this Registration
Statement:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company&#146;s Annual Report on Form 10-K for the year ended December&nbsp;31, 2007, filed
with the SEC on March&nbsp;25, 2008;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company&#146;s Proxy Statement for the 2008 Annual Meeting of Stockholders to be held on
June&nbsp;18, 2008, filed with the SEC on April&nbsp;29, 2008;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company&#146;s Quarterly Report on Form 10-Q for the three months ended March&nbsp;31, 2008,
filed with the SEC on May&nbsp;15, 2008;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company&#146;s description of its common stock contained in its Registration Statement
on Form 8-A, filed with the Commission on September&nbsp;29, 2006, along with Amendment No.&nbsp;1
thereto, filed with the Commission on October&nbsp;18, 2006; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All documents subsequently filed by the Company pursuant to Sections&nbsp;13(a), 13(c), 14
and 15(d) of the Exchange Act, from the date of filing of such documents, before the filing
of a post-effective amendment to this Registration Statement which indicates that all
securities offered hereunder have been sold or which deregisters all securities then
remaining unsold.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Any statement contained in a document incorporated or deemed to be incorporated by reference herein
shall be deemed to be modified or superseded for purposes of this Registration Statement to the
extent that a statement contained herein or in any other subsequently filed document, which also is
incorporated or deemed to be incorporated by reference herein, modifies or supersedes such
statement. Any such statement so modified or superseded shall not be deemed, except as so modified
or superseded, to constitute a part of this Registration Statement.
</DIV>

<!-- link2 "Item&nbsp;4. Description of Securities." -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;4. Description of Securities.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The class of securities to be offered is registered under Section&nbsp;12 of the Securities Exchange Act
of 1934.
</DIV>

<!-- link2 "Item&nbsp;5. Interests of Named Experts and Counsel." -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;5. Interests of Named Experts and Counsel.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The legality of the shares of Common Stock registered hereby has been passed upon for the Company
by Akerman Senterfitt LLP, Miami, Florida. As of the date of this Registration Statement, certain
attorneys employed by Akerman Senterfitt LLP beneficially own shares of the Company&#146;s Common Stock.
</DIV>

<!-- link2 "Item&nbsp;6. Indemnification of Directors and Officers." -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;6. Indemnification of Directors and Officers.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Section&nbsp;145 of the Delaware General Corporation Law (the &#147;DGCL&#148;) provides that a corporation may
indemnify directors and officers as well as other individuals against expenses, judgments, fines
and amounts paid in settlement actually and reasonably incurred by such person in connection with
any
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->II-1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">threatened, pending or completed actions, suits or proceedings in which such person is made a party
by reason of such person being or having been a director, officer, employee or agent to the
Registrant. The DGCL provides that Section&nbsp;145 is not exclusive of other rights to which those
seeking indemnification may be entitled under any bylaw, agreement, vote of stockholders or
disinterested directors or otherwise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;VII of the Company&#146;s Certificate of Incorporation provides that no director of the Company
shall be personally liable to the Company or its stockholders for monetary damages for breach of
fiduciary duty as a director, except for liability (i)&nbsp;for any breach by a director of the duty of
loyalty to the Company or its stockholders, (ii)&nbsp;for acts or omissions not in good faith or which
involve intentional misconduct or a knowing violation of law, (iii)&nbsp;for violations of Section&nbsp;174
of the DGCL, or (iv)&nbsp;for any transaction from which the director derived an improper personal
benefit.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Certificate of Incorporation further provides that any amendment of the DGCL that
authorizes corporate action further eliminating or limiting the personal liability of directors,
the liability of a director of the Company shall be eliminated or limited to the fullest extent as
permitted by the DGCL, as amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;VI of the By-Laws of the Company (the &#147;Bylaws&#148;) provides that the Company shall indemnify
and hold harmless, to the fullest extent permitted by applicable law as it presently exists or may
hereafter be amended, any person (a &#147;Covered Person&#148;) who was or is threatened to be made a party
or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative
or investigative (a &#147;proceeding&#148;) by reason of the fact that he or she, or a person for whom he or
she is the legal representative, is or was a director or officer of the Company, is or was serving
at the request of the Company as a director, officer, employee or agent of another corporation or
partnership, joint venture, trust, enterprise or nonprofit entity, including service with respect
to employee benefit plans, against all liability and loss suffered and expenses (including
attorneys&#146; fees) reasonably incurred by such Covered Person. The Company is further required to
indemnify a Covered Person in connection with a proceeding commenced by such Covered Person only if
the commencement of such proceeding by the Covered Person was authorized in the specific case by
the Board of Directors of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Bylaws provide that the Company shall, to the fullest extent not prohibited by applicable law,
pay the expenses (including attorneys&#146; fees) incurred by a Covered Person in defending any
proceeding in advance of its final disposition, provided, however, that to the extent required by
law, such payment of expenses in advance of the final disposition of the proceeding shall be made
only upon receipt of an undertaking by the Covered Person to repay all amounts advanced if it is
ultimately determined that the Covered Person is not eligible to be repaid under Article&nbsp;VI of the
Bylaws or otherwise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Bylaws provide that if a claim for indemnification (following the final disposition of such
action, suit or proceeding) or advancement of expenses under the Bylaws is not paid in full within
thirty days after a written claim therefor by the Covered Person has been received by the Company,
the Covered Person may file suit to recover the unpaid amount of such claim, and, if successful in
whole or in part, shall be entitled to be paid the expense of prosecuting such claim. In any such
action the Company shall have the burden of proving that the Covered Person is not entitled to the
requested indemnification or advancement of expenses under applicable law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Bylaws provide that the rights conferred on any person under Article&nbsp;VI thereof shall not be
exclusive of any other rights which such Covered Person may have or thereafter acquire under any
statute, provision of the Certificate of Incorporation, the Bylaws, agreement, vote of stockholders
or disinterested directors or otherwise.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->II-2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Bylaws provide that the Company&#146;s obligation, if any, to indemnify or to advance expenses to
any Covered Person who was or is serving at its request as a director, officer, employee or agent
of another corporation, partnership, joint venture, trust, enterprise or nonprofit entity shall be
reduced by the amount such Covered Person may collect as indemnification or advancement of expenses
from such other corporation, partnership, joint venture, trust, enterprise or non-profit
enterprise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Bylaws provide that any repeal or modification of the provisions of Article&nbsp;VI thereof shall
not adversely affect any right or protection thereunder of any Covered Person in respect of any act
or omission occurring prior to the time of such repeal or modification.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Bylaws provide that indemnification under Article&nbsp;VI thereof shall not limit the right of the
Company, to the extent and in the manner provided by law, to indemnify and to advance expenses to
persons other than Covered Persons when and as authorized by appropriate corporate action.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Insofar as indemnification for liabilities arising under the Securities Act of 1933, as
amended, is permitted to directors and officers of the Company pursuant to the above statutory
provisions, the Company understands that the Securities and Exchange Commission is of the opinion
that such indemnification contravenes federal public policy as expressed in said act and therefore
is unenforceable.
</DIV>

<!-- link2 "Item&nbsp;7. Exemption from Registration Claimed." -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;7. Exemption from Registration Claimed.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Not applicable.
</DIV>

<!-- link2 "Item&nbsp;8. Exhibits." -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;8. Exhibits.</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="97%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left">Exhibit No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">Description</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Certificate of Incorporation of Catalyst Pharmaceutical
Partners, Inc. (incorporated by reference to Exhibit&nbsp;3.1 to
the Company&#146;s Registration Statement on Form&nbsp;S-1, filed on
July&nbsp;25, 2006).</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Certificate of Amendment to the Certificate of Incorporation
of Catalyst Pharmaceutical Partners, Inc. (incorporated by
reference to Exhibit&nbsp;3.2 of the Company&#146;s Registration
Statement on Form&nbsp;S-1, filed on July&nbsp;25, 2006).</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.3
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Bylaws of Catalyst Pharmaceutical Partners, Inc. (incorporated
by reference to Exhibit&nbsp;3.3 to the Company&#146;s Registration
Statement on Form&nbsp;S-1, filed on July&nbsp;25, 2006).</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">5.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Opinion of Akerman Senterfitt.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Non-Qualified Stock Option
Agreements between the Company and
Patrick J. McEnany (incorporated by reference to Exhibit&nbsp;10.4
to the Company&#146;s Registration Statement on Form&nbsp;S-1, filed on
July&nbsp;25, 2006).</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Non-Qualified Stock Option
Agreements between the Company and
Hubert E. Huckel, M.D. (incorporated by reference to Exhibit
10.5 to the Company&#146;s Registration Statement on Form&nbsp;S-1,
filed on July&nbsp;25, 2006).</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.3
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Non-Qualified Stock Option
Agreements between the Company and
Jack Weinstein (incorporated by reference to Exhibit&nbsp;10.6 to
the Company&#146;s Registration Statement on Form&nbsp;S-1, filed on
July&nbsp;25, 2006).</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.4
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Non-Qualified Stock Option Agreement between the Company and
Charles O&#146;Keeffe (incorporated by reference to Exhibit&nbsp;10.7 to
the Company&#146;s Registration Statement on Form&nbsp;S-1, filed on
July&nbsp;25, 2006).</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->II-3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="97%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left">Exhibit No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">Description</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.5
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Non-Qualified Stock Option Agreement between the Company and
M. Douglas Winship (incorporated by reference to Exhibit&nbsp;10.3
to the Company&#146;s Quarterly Report for the Three and Nine
Months Ended September&nbsp;30, 2006, filed on December&nbsp;12, 2006)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.6
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Consulting Agreement between the Company and Dr.&nbsp;Donald
Jasinski (incorporated by reference to Exhibit&nbsp;10.12 to
Amendment No.&nbsp;1 to the Company&#146;s Registration Statement on
Form&nbsp;S-1, filed with the Commission on September&nbsp;1, 2006)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">23.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Consent of Akerman Senterfitt (Included in Exhibit&nbsp;5.1).</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">23.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Consent of Grant Thornton LLP.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">24.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Power of Attorney (included in the signature pages to this
Registration Statement).</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<!-- link2 "Item&nbsp;9. Undertakings." -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9. Undertakings.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The undersigned registrant hereby undertakes:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To file, during any period in which offers or sales are being made, a post-effective
amendment to this registration statement:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To include any prospectus required by Section&nbsp;10(a)(3) of the
Securities Act of 1933;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To reflect in the prospectus any facts or events arising after the
effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental
change in the information set forth in the registration statement. Notwithstanding
the foregoing, any increase or decrease in volume of securities offered (if the
total dollar value of securities offered would not exceed that which was
registered) and any deviation from the low or high end of the estimated maximum
offering range may be reflected in the form of prospectus filed with the Commission
pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price
represent no more than 20% change in the maximum aggregate offering price set forth
in the &#147;Calculation of Registration Fee&#148; table in the effective registration
statement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">c.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To include any material information with respect to the plan of
distribution not previously disclosed in the registration statement or any material
change to such information in the registration statement;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Provided however, that paragraphs (a)(1)(a) and (a)(1)(b) above do not apply if the
information required to be included in a post-effective amendment by those paragraphs is
contained in reports filed with or furnished to the Commission by the registrant pursuant to
section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by
reference in the registration statement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>That, for the purpose of determining any liability under the Securities Act of 1933,
each such post-effective amendment shall be deemed to be a new registration statement
relating to the
</TD>
</TR>
</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->II-4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>securities offered therein, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To remove from registration by means of a post-effective amendment any of the
securities being registered which remain unsold at the termination of the offering.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The undersigned registrant hereby undertakes that, for purposes of determining any
liability under the Securities Act of 1933, each filing of the registrant&#146;s annual report
pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and,
where applicable, each filing of an employee benefit plan&#146;s annual report pursuant to
section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in
the registration statement shall be deemed to be a new registration statement relating to
the securities offered therein, and the offering of such securities at that time shall be
deemed to be the initial bona fide offering thereof.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be
permitted to directors, officers and controlling persons of the registrant pursuant to the
foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the
Securities and Exchange Commission such indemnification is against public policy as expressed in
the Act and is, therefore, unenforceable. In the event that a claim for indemnification against
such liabilities (other than the payment by the registrant of expenses incurred or paid by a
director, officer or controlling person of the registrant in the successful defense of any action,
suit or proceeding) is asserted by such director, officer or controlling person in connection with
the securities being registered, the registrant will, unless in the opinion of its counsel the
matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Act and
will be governed by the final adjudication of such issue.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->II-5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the requirements of the Securities Act of 1933, as amended, Catalyst Pharmaceutical
Partners, Inc. certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-8 and has duly caused this Registration Statement on Form S-8 to
be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Coral Gables,
State of Florida, on June&nbsp;2, 2008.
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>CATALYST PHARMACEUTICAL<BR>
PARTNERS, INC.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Patrick J. McEnany
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Patrick J. McEnany, Chairman,&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">President and CEO&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>POWER OF ATTORNEY</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each person whose signature appears below hereby constitutes and appoints Patrick J. McEnany
and Jack Weinstein, and each of them, as his true and lawful attorneys-in-fact and agents, with
full power of substitution and resubstitution for him and in his name, place, and stead, in any and
all capacities, to sign any or all amendments or supplements to this registration statement,
whether pre-effective or post-effective, including any subsequent registration statement for the
same offering which may be filed under Rule 462(b) under the Securities Act of 1933, as amended, to
file the same with all exhibits thereto and other documents in connection therewith, with the
Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of
them, full power and authority to do and perform each and every act and thing necessary or
appropriate to be done with respect to this registration statement or any amendments or supplements
hereto in the premises, as fully to all intents and purposes as he might or could do in person,
hereby ratifying and confirming that all said attorneys-in-fact and agents, or any of them, or this
or his substitute or substitutes, may lawfully do or cause to be done by virtue thereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, this report has been signed by the
following persons, in the capacities and on the dates indicated.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="37%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Signature</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Title</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Date</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Patrick J. McEnany
<DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
Patrick J. McEnany
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Chairman of the Board
of<BR> Directors,
President and Chief<BR>
Executive Officer
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">June&nbsp;2, 2008</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Jack Weinstein<BR>
<DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
Jack Weinstein
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" valign="top">Vice President, Treasurer
and<BR> Chief
Financial Officer
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">June&nbsp;2, 2008</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Alicia Grande<BR>
<DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
Alicia Grande
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Corporate Controller/Chief<BR>
Accounting Officer
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">June&nbsp;2, 2008</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Hubert E. Huckel, M.D.
<DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
Hubert E. Huckel, M.D.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Director
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">June&nbsp;2, 2008</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Charles B. O&#146;Keeffe
<DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
Charles B. O&#146;Keeffe
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Director
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">June&nbsp;2, 2008</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="37%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Signature</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Title</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Date</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Philip H. Coelho
<DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
Philip H. Coelho
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Director
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">June&nbsp;2, 2008</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ David S. Tierney, M.D.
<DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
David S. Tierney, M.D.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Director
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">June&nbsp;2, 2008</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Milton J. Wallace
<DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
Milton J. Wallace
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Director
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">June&nbsp;2, 2008</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
[{"type": "S-8", "sequence": "1", "filename": "g13728sv8.htm", "description": "CATALYST PHARMACEUTICAL PARTNERS, INC.", "secsgml_size_bytes": 117424}]
{"company-data": {"conformed-name": "Catalyst Pharmaceutical Partners, Inc.", "cik": "0001369568", "assigned-sic": "2834", "irs-number": "000000000", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-151369", "film-number": "08874962"}, "business-address": {"street1": "220 MIRACLE MILE", "street2": "SUITE 234", "city": "CORAL GABLES", "state": "FL", "zip": "33134", "phone": "(305) 529-2522"}, "mail-address": {"street1": "220 MIRACLE MILE", "street2": "SUITE 234", "city": "CORAL GABLES", "state": "FL", "zip": "33134"}}
CATALYST PHARMACEUTICAL PARTNERS, INC.
Table of Contents
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Catalyst Pharmaceutical Partners, Inc.
(Exact name of registrant as specified in its charter)
Delaware
76-0837053
(State or Other Jurisdiction of
Incorporation or Organization)
(I.R.S. Employer Identification No.)
355 Alhambra Circle
Suite 1370
Coral Gables, Florida 33134
(Address of Principal Executive Offices)
(Zip Code)
Patrick J. McEnany Non-Qualified Stock Option Agreements
Hubert E. Huckel Non-Qualified Stock Option Agreements
Jack Weinstein Non-Qualified Stock Option Agreements
M. Douglas Winship Stock Option Agreement
Charles B. O'Keeffe Non-Qualified Stock Option Agreement
Donald R. Jasinski Consulting Agreement
(Full Titles of the Plans)
Patrick J. McEnany
355 Alhambra Circle, Suite 1370
Coral Gables, Florida 33134
(Name and Address of Agent for Service)
With a copy to:
Philip B. Schwartz, Esq.
Akerman Senterfitt
One Southeast Third Avenue, 25
th
Floor
Miami, Florida 33131
(305) 374-5600
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer
o
Accelerated filer
o
Non-accelerated filer
o
(Do not check if a smaller reporting company)
Smaller reporting company
x
Table of Contents
CALCULATION OF REGISTRATION FEE
Title of Each Class
Proposed Maximum
Proposed Maximum
of Securities to be
Amount to be
Offering Price Per
Aggregate Offering
Amount of
Registered
Registered (1)
Share (2)
Price
Registration Fee
Common Stock
2,352,254
$
3.59
$
8,445,000
$
331.89
(1)
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"),
this Registration Statement on Form S-8 also covers an indeterminate number of additional shares of
common stock that may become issuable in the future under the various stock option plans as a
result of stock splits, stock dividends or other similar transactions.
(2)
Estimated solely for the purpose of computing the registration fee. This amount was calculated
pursuant to Rule 457(h) under the Securities Act on the basis of $3.59 per share, which was the
average of the high and low sale prices of the Registrant's common stock on the Nasdaq Global
Market on May 30, 2008.
Table of Contents
EXPLANATORY NOTE
Catalyst Pharmaceutical Partners, Inc. (the "Registrant" or the "Company") has prepared this
Registration Statement in accordance with the requirements of Form S-8 under the Securities Act of
1933 to register an aggregate of 2,352,254 shares of its common stock, par value $0.001 per share,
issuable upon the exercise of stock options granted to some of its
directors, employees, officers
and scientific advisors. This Registration Statement also includes a reoffer prospectus. Certain
shares offered by the reoffer prospectus are "control securities" (as defined in General
Instruction C to Form S-8). The other shares covered by the reoffer prospectus are "restricted
securities" (as defined in General Instruction C to Form S-8)
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
Information required by Item 1 to be contained in the Section 10(a) prospectus is omitted from this
Registration Statement in accordance with Rule 428 under the Securities Act and the Note to Part I
of Form S-8. This information will be sent or given to all persons with whom we have stock option
agreements as specified by Rule 428(b)(1) of the Securities Act. This information and the
documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of
this Registration Statement, constitute a prospectus that meets the requirements of Section 10(a)
of the Securities Act.
The reoffer prospectus referred to in the Explanatory Note follows this page.
Table of Contents
2,352,254 Shares
CATALYST PHARMACEUTICAL PARTNERS, INC.
COMMON STOCK
This prospectus relates to 2,352,254 shares of our common stock that may be offered and resold
from time to time by the selling stockholders identified in this reoffer prospectus for their own
accounts. The shares offered in this prospectus were issued pursuant to various stock option
agreements with the selling stockholders. All of the selling stockholders are directors, officers,
employees or scientific advisors to and of our company. We will receive no part of the proceeds
from sales made under this prospectus.
The shares of common stock covered by this prospectus are "restricted securities" and, in some
cases, "control securities" under the Securities Act of 1933, as amended (the "Securities Act").
This prospectus has been prepared to allow for future resales of the shares covered by this
prospectus by the selling stockholders, on a continuous or delayed basis, to the public. The number
of shares that each selling stockholder may sell is set forth under Rule 144(e) under the
Securities Act. Each stockholder that resells shares of our common stock pursuant to this
prospectus may be deemed an "underwriter" within the meaning of the Securities Act. Any commissions
received by a broker or dealer in connection with resales of shares of our commons tock covered by
this prospectus may be deemed to be underwriting commissions or discounts under the Securities Act.
The selling stockholders, or their pledgees, donees, transferees or other
successors-in-interest, may resell their shares of common stock covered by this prospectus from
time to time in one or more public or private transactions at prevailing market prices, at prices
related to prevailing market prices or at privately negotiated prices.
We are paying the expenses incurred in registering the shares covered by this prospectus and
the preparation of this prospectus, but all selling and other expenses, including but not limited
to any discounts, commissions and applicable transfer taxes, incurred by each of the selling
stockholders will be borne by such stockholder.
Our common stock is listed on the Nasdaq Global Market under the symbol "CPRX". On May 30, 2008,
2008, the last reported sale price of our common stock was $3.59 per share.
Our principal executive officers are located at 355 Alhambra Circle, Suite 1370, Coral Gables,
Florida 33134. Our telephone number is (305) 529-2522.
INVESTING IN OUR COMMON STOCK INVOLVES RISKS. SEE "
RISK FACTORS
" ON PAGE 6 OF THIS
PROSPECTUS FOR A DISCUSSION OF THOSE RISKS.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS
APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR
COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
The date of this reoffer prospectus is June 2, 2008.
TABLE OF CONTENTS
Available Information
3
Incorporated Documents
3
Certain Definitions
4
The Company
4
Risk Factors
6
Special Note Regarding Forward-Looking Statements
6
Use of Proceeds
7
Dividend Policy
7
Selling
Stockholders
7
Plan of Distribution
9
Disclosure of SEC's Position on Indemnification for Securities Act Liabilities
12
Legal Matters
12
Experts
12
EX-5.1 OPINION of AKERMAN SENTERFITT LLP
EX-23.2 CONSENT OF GRANT THORNTON LLP.
You should rely only on the information included or incorporated by reference in this
prospectus. We have not authorized anyone else to provide you with different information. If anyone
provides you with different or inconsistent information, you should not rely on it. The shares of
common stock covered by this prospectus are not being offered or sold in any jurisdiction where
such offer or sale is not permitted. You should not assume that the information included or
incorporated by reference in this prospectus is accurate as of any date other than the date on the
front cover of this prospectus. Our business, financial condition, results of operations and
prospects may have changed since that date.
2
Table of Contents
AVAILABLE INFORMATION
We are subject to the informational reporting requirements of the Securities Exchange Act of
1934, as amended (the "Exchange Act"), and file reports, proxy statements and other information
with the Securities and Exchange Commission (the "SEC"). You may read and copy any document that we
file at the SEC's Public Reference Room, which is located at 100 F Street, NE, Washington, DC
20549. Please call 1-800-SEC-0330 for further information on the SEC's Public Reference Room. Our
SEC filings are also available to the public at the SEC's
website at
http://www.sec.gov
.
We
also make available on our website,
http://www.catalystpharma.com
, free of charge, the
documents we file with the SEC, as soon as is practicable after we file documents with the SEC.
Information on or connected to our web site shall not be deemed to be a part of this prospectus.
We have filed with the SEC hereunder a Registration Statement on Form S-8 under the Securities
Act covering the shares of our common stock to be resold from time to time under this prospectus by
certain selling stockholders covered by this prospectus pursuant to the various stock option
agreements and their pledgees, donees, transferees or other successors in interest. The SEC permits
us to omit from this prospectus certain information, exhibits and undertakings contained in the
Registration Statement.
You should rely only on the information incorporated by reference or provided in this
prospectus or a prospectus supplement accompanying this prospectus. We have not authorized anyone
to provide you with different information. If anyone provides you with different or inconsistent
information, you should not rely on it. The shares of common stock covered by this prospectus are
not being offered or sold in any jurisdiction where the offer or sale is not permitted. You should
not assume that the information in this prospectus is accurate as of any date other than the date
on the front of this prospectus, since our business, financial condition, results of operations
and prospects may have changed since that date.
INCORPORATED DOCUMENTS
The SEC allows us to "incorporate by reference" information into this prospectus, which means
that we can disclose important information to you by referring you to another document filed
separately with the SEC. The information incorporated by reference is deemed to be a part of this
prospectus, except for any information superseded by information in this prospectus or by any
information in a prospectus supplement accompanying this prospectus.
The following documents filed with the SEC are incorporated by reference in this prospectus:
1.
Our Annual Report on Form 10-K for the year ended December 31, 2007, filed with the SEC
on March 25, 2008;
2.
Our Proxy Statement for the 2008 Annual Meeting of Stockholders to be held on June 18,
2008, filed with the SEC on April 29, 2008;
3.
Our Quarterly Report on Form 10-Q for the three months ended March 31, 2008, filed with
the SEC on May 15, 2008; and
4.
Our description of our common stock contained in our Registration Statement on Form
8-A, filed with the SEC on September 29, 2006, along with Amendment No. 1 thereto, filed
with the SEC on October 18, 2006.
3
Table of Contents
This
Registration Statement on Form S-8 also incorporates by reference all documents
subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange
Act, from the date of filing of such documents, before the filing of a post-effective amendment to
this Registration Statement which indicates that all securities offered hereunder have been sold or
which deregisters all securities then remaining unsold.
You may obtain a copy of any of these documents at no cost by requesting them from us or by
writing or calling: Catalyst Pharmaceutical Partners, Inc., 355 Alhambra Circle, Suite 1370, Coral
Gables, Florida, 33134, Attn: Investor Relations, or by calling (305) 529-2522.
CERTAIN DEFINITIONS
Except where the context suggests otherwise, "we", "us", "our", and "the Company" refer to
Catalyst Pharmaceutical Partners, Inc.
THE COMPANY
We are a development-stage biopharmaceutical company focused on the acquisition, development
and commercialization of prescription drugs for the treatment of drug addiction and obsessive
compulsive disorders. Our initial product candidate is CPP-109, which is our version of vigabatrin.
The successful development of CPP-109 or any other product we may develop, acquire, or license
is highly uncertain. We cannot reasonably estimate or know the nature, timing, or estimated
expenses of the efforts necessary to complete the development of, or the period in which material
net cash inflows are expected to commence due to the numerous risks and uncertainties associated
with developing, such products, including the uncertainty of:
•
the scope, rate of progress and expense of our clinical trials and our other product
development activities;
•
the results of future clinical trials, and the number of clinical trials (and the
scope of such trials) that will be required to seek and obtain approval of a new drug
application, or NDA, for CPP-109; and
•
the expense of filing, prosecuting, defending and enforcing any patent claims and
other intellectual property rights.
Our principal executive offices are located at 355 Alhambra Circle, Suite 1370, Coral Gables,
Florida 33134. Our telephone number is (305) 529-2522. Our website is
http://www.catalystpharma.com
. The information contained in, or that can be accessed
through, our website is not a part of this prospectus.
Recent Developments
U.S. Phase II clinical trial for cocaine addiction
During July 2007, we initiated a randomized, double-blind, placebo-controlled U.S. Phase II
clinical trial evaluating the use of CPP-109 in treating patients with cocaine addiction. We estimate that the cost of this trial will be approximately $6,000,000.
4
Table of Contents
The trial is expected to enroll 180 cocaine addicted patients at not less than 11 addiction
treatment clinical centers in the United States. Patients will be treated for a period of 12 weeks,
with an additional 12 weeks of follow-up. The primary endpoint of the trial is to demonstrate that
a larger proportion of CPP-109-treated subjects than placebo-treated subjects will be cocaine-free
during their last two weeks of treatment (weeks 11 and 12). Additionally, we will be measuring
several secondary endpoints based on reductions of cocaine use and craving. To be eligible to
participate in this trial, participants must meet specific clinical standards for cocaine
dependence, as specified in DSM-IV, a set of diagnosis guidelines established for clinical
professionals. Additionally, trial participants cannot meet the DSM-IV criteria for dependence on
most other addictive substances. Further, eye safety studies will be conducted on all trial
participants before and after the trial to determine the extent of visual field defects that may
occur as a result of the trial among such participants, if any. We began enrolling patients in our
trial in January 2008 after the protocol for our trial was accepted by the U.S. Food and Drug
Administration ("FDA"). Based on currently available information, we expect to have initial
top-line results from this trial in the fourth quarter of 2008. However, the date we obtain the
results from our study will ultimately depend on the timing of patient enrollment into our study,
which cannot be predicted with absolute certainty. Additional information about our trial can be
found at
www.clinicaltrials.gov
.
U.S. Phase II clinical trial for methamphetamine addiction
We expect to initiate during the second quarter of 2008 a 180 patient randomized, double-blind, placebo-controlled U.S.
Phase II clinical trial evaluating the use of CPP-109 in treating patients with methamphetamine
addiction. This trial will be similar to our cocaine trial. We currently estimate that the cost of this trial will
be approximately $5,900,000. Based on currently available information, we expect to have initial
top-line results from this trial during the third quarter of 2009.
5
Table of Contents
Contemplated pilot clinical trials
We hope to initiate during 2008 a Phase II clinical trial evaluating CPP-109 for the treatment
of binge eating disorder or BED. BED, which impacts a subset of the obese population, affects
approximately four million people in the United States. We are also contemplating and hope to
launch during 2008 additional Phase II proof-of-concept trials evaluating the use of CPP-109 for
the treatment of other addictions, including alcohol and nicotine.
Discussions with strategic partners
We
have had in the past, and expect to continue to have in the future, discussions with potential strategic partners interested in working with
us on the development of CPP-109. No agreements have been entered into to date with
any potential strategic partners.
RISK FACTORS
Before making an investment decision, you should carefully consider the risks described under
"Risk Factors" in the applicable prospectus supplement and in our most recent Annual Report on Form
10-K, or any updates in subsequent Quarterly Reports on Form 10-Q, together with all of the other
information appearing in this prospectus or incorporated in this prospectus by reference and any
applicable prospectus supplement, in light of your particular investment objectives.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Some of the statements provided in or incorporated by reference by this prospectus contain
"forward-looking statements," including statements regarding our expectations, beliefs, plans or
objectives for future operations and anticipated results of operations. For this purpose, any
statements contained herein that are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the foregoing, the words, "believes," "anticipates,"
"proposes," "plans," "expects," "intends," "may" and similar expressions are intended to identify
forward-looking statements. Such statements involve known and unknown risks, uncertainties and
other factors that may cause our actual results, performance or achievements to be materially
different from any future results, performance or achievements expressed or implied by such
forward-looking statements. The forward-looking statements made in this prospectus are based on
current expectations that involve numerous risks and uncertainties, including but not limited to
the following:
•
our having sufficient financial resources;
•
our ability to successfully complete our clinical and non-clinical trials required for us to file and obtain
approval of a NDA for our product candidate CPP-109;
•
our ability to complete such trials on a timely basis and within the budgets we establish
for such trials;
•
our ability to protect our intellectual property;
•
whether others develop and commercialize products competitive to our products;
•
changes in the regulations affecting our business;
•
our ability to attract and retain skilled employees; and
6
Table of Contents
•
changes in general economic conditions and interest rates.
Our current plans and objectives are based on assumptions relating to the development of our
business. Although we believe that our assumptions are reasonable, any of our assumptions could
prove inaccurate. In light of the significant uncertainties inherent in the forward-looking
statements made herein, which reflect our views only as of the date of this prospectus, you should
not place undue reliance upon such statements. We undertake no obligation to update or revise
publicly any forward-looking statements, whether as a result of new information, future events or
otherwise.
USE OF PROCEEDS
We will not receive any of the proceeds from the resale of the shares of our common stock
covered by this prospectus. We will pay all costs and expenses incurred by us in connection with
the registration under the Securities Act of the shares of our common stock covered by this
prospectus.
DIVIDEND POLICY
We do not anticipate that we will pay any cash dividend on our common stock in the foreseeable
future. We intend to retain all available funds and any future earnings to fund the development and
growth of our business.
SELLING STOCKHOLDERS
This prospectus permits the resale of up to 2,352,254 shares of common stock by the selling
stockholders identified below and their pledgees, donees, transferees and other successors in
interest that receive shares from a selling stockholder as a gift, distribution or other non
sale-related transfer after the date of this prospectus (all of whom may be selling stockholders
for purposes of this prospectus). The shares of common stock covered by this prospectus may be
offered and resold when and as the selling stockholders deem appropriate. All of the selling
stockholders are directors, officers, employees or advisors of or scientific advisors to our
company. The selling stockholders acquired these shares from us pursuant to awards or stock option
grants under individual stock option agreements. The shares of common stock covered by this
prospectus may not be sold or otherwise transferred by the selling stockholders named in the table
below unless and until the restrictions on sales or other transfers applicable to the shares of
common stock acquired under such agreements lapse in accordance with the terms and conditions of
such agreements and any applicable grant instrument.
The following table sets forth: (i) the name of each selling stockholder; (ii) any position,
office or other material relationships with our company, over the last three years of each selling
stockholder; (iii) the number and percentage of shares of our common stock, known to us, that each
selling stockholder beneficially owned prior to the offering for resale of the shares under this
prospectus; (iv) the number of shares of common stock that may be offered for resale for the
account of each selling stockholder under this prospectus; and (v) the number and percentage of
shares of common stock to be beneficially owned by each selling stockholder after the offering of
the shares under this prospectus (assuming all of the shares under this prospectus are sold for the
account of each selling stockholder and no other shares of common stock are acquired or sold by
each selling stockholder).
The number of shares in the column "Number of Shares Being Offered" represents all of the
shares of common stock that each selling stockholder may offer under this prospectus. We do not
know
7
Table of Contents
how long the selling stockholders will hold these shares before selling them or how many shares
they will sell. We currently have no agreements, arrangements or understandings with any of the
selling stockholders regarding the sale of any of the shares covered by this prospectus. The
shares of common stock offered by this prospectus may be offered from time to time by the selling
stockholders listed below as described in this prospectus under the heading "Plan of Distribution."
We cannot assure you that any of the selling stockholders listed below will offer or resell any or
all of the shares of common stock offered by them by this prospectus.
Unless indicated otherwise in the notes to the table below, each selling stockholder has sole
voting and sole investment power over the shares of common stock beneficially owned by each selling
stockholder, and the address of each selling stockholder is c/o Catalyst Pharmaceutical Partners,
Inc., 355 Alhambra Circle, Suite 1370, Coral Gables, Florida 33134.
Number of Shares
Shares Beneficially Owned
Beneficially Owned
Number of Shares
After Offering (2)
Name
Prior to Offering (1)
Being Offered (2)
Number
Percentage
Huckel, Hubert (3)
1,913,742
729,608
1,184,134
6.9
Jasinski, Donald (4)
17,510
17,510
—
*
McEnany, Patrick (5)
3,975,894
729,608
3,246,286
19.0
O'Keeffe, Charles (6)
360,619
291,843
68,776
*
Weinstein, Jack (7)
443,761
437,764
5,997
*
Winship, M. Douglas (8)
145,921
145,921
—
*
*
Less than one percent
(1)
Beneficial ownership has been determined in accordance with Rule 13d-3 under the Exchange Act.
A person is deemed to be the beneficial owner of shares of common stock if that person has or
shares voting power or investment power with respect to those shares or has the right to acquire
beneficial ownership of those shares within 60 days of June 2008.
(2)
Assumes that all shares of common stock to be offered are sold pursuant to this offering and
that no other shares of common stock are acquired or disposed of by the selling stockholders prior
to the termination of this offering. Because the selling stockholders or their pledgees, donees,
transferees, or other successors in interest may sell all, some or none of the shares of common
stock covered by this prospectus or may acquire or dispose of other shares of our common stock, no
reliable estimate can be made of the aggregate number of shares of common stock that will be sold
pursuant to this offering. The percentage of shares beneficially owned by each selling stockholder
after this offering is based on the 12,567,226 shares of common stock outstanding as of April 29,
2008.
(3)
Dr. Huckel serves as a director of the Company
(4)
Dr. Jasinski is a consultant to the Company and serves on the Company's Scientific Advisory
Board.
(5)
Mr. McEnany serves as Chairman of the Board, President and Chief Executive Officer of the
Company.
(6)
Mr. O'Keeffe is a Consultant to the Company and serves on the Company's Board of Directors.
(7)
Mr. Weinstein serves as a Vice President, Treasurer and Chief Financial Officer of the Company
(8)
Mr. Winship serves as the Company's Vice President of Regulatory Operations.
8
Table of Contents
PLAN OF DISTRIBUTION
The purpose of this prospectus is to permit each selling stockholder and his or her pledgees,
donees, transferees and other successors in interest (all of whom may be selling stockholders for
purposes of this prospectus) to offer and resell all or a portion of the shares the selling
stockholders have acquired pursuant to the stock option agreements. The selling stockholders may
also choose to dispose of all or a portion of the shares of common stock covered by this prospectus
by gift to a third party or as a donation to a charitable or other nonprofit entity.
The sale of the common stock by any selling stockholder, including any donee, pledgee or other
transferee who receives common stock from a selling stockholder, may be effected from time to time
by selling shares directly to purchasers or to or through broker-dealers. In connection with any
such sale, any such broker dealer may act as agent for the selling stockholder or may purchase from
the selling stockholder all or a portion of the common stock as principal, and sales may be made
pursuant to any of the methods described below. These sales may be made on any securities exchange
on which our common stock is then traded, in the over-the-counter market, in negotiated
transactions or otherwise at prices and at terms then prevailing or at prices related to the then
current market prices or at prices otherwise negotiated.
The common stock may also be sold in one or more of the following transactions:
•
block transactions (which may involve crosses) in which a broker dealer may sell all or a
portion of such securities as agent but may position and resell all or a portion of the block
as principal to facilitate the transaction;
•
purchases by a broker dealer, as principal, and resale by such broker dealer for its own
account pursuant to a prospectus supplement;
•
a special offering, an exchange distribution or a secondary distribution in accordance with
applicable rules promulgated by the National Association of Securities Dealers, or stock
exchange rules;
•
ordinary brokerage transactions and transactions in which a broker dealer solicits
purchasers;
•
sales "at the market" to or through a market maker or into an existing trading market, on
an exchange or otherwise, for such securities; and
•
sales in other ways not involving market markers or established trading markets, including
direct sales to purchasers.
In effecting sales, broker-dealers engaged by a selling stockholder may arrange for other
broker-dealers to participate. Broker-dealers may receive commissions or other compensation from
the selling stockholder in the form of commissions, discounts or concessions. Broker-dealers may
also receive compensation from purchasers of the common stock for whom they act as agents or to
whom they sell as principals or both. Compensation as to a particular broker dealer will be in
amounts to be negotiated. The selling stockholders do not expect these commissions and discounts to
exceed what is customary in the type of transactions involved. No such broker dealer will receive
compensation in excess of that permitted by the rules of the Financial Industry Regulatory
Authority, or FINRA. In no event will any broker dealer receive total compensation in excess of the
maximum amount allowed by FINRA.
The distribution of the common stock covered by this prospectus also may be effected from time
to time in one or more underwritten transactions at a fixed price or prices that may be changed, or
at
9
Table of Contents
market prices prevailing at the time of sale, at prices related to such prevailing market prices or
at negotiated prices. Any such underwritten offering may be on a "best efforts" or a "firm
commitment" basis. In connection with any underwritten offering, underwriters or agents may receive
compensation in the form of discounts, concessions or commissions from the selling stockholders or
from purchasers of the common stock. Underwriters may sell the common stock to or through dealers,
and such dealers may receive compensation in the form of discounts, concessions or commissions from
the underwriters and/or commissions from the purchasers for whom they may act as agents.
The selling stockholders have advised us that they have not entered into any agreements,
understandings or arrangements with any underwriters or broker-dealers regarding the sale of their
common stock covered by this prospectus, nor is there any underwriter or coordinating broker dealer
acting in connection with the proposed sale of common stock by the selling stockholders pursuant to
this prospectus. We will file a supplement to this prospectus, if required, under Rule 424(b) under
the Securities Act that will include any material information with respect to the plan of
distribution not previously disclosed or any material change in such information. This supplement
will disclose, among other information:
•
the names of the selling stockholders and of participating broker dealer(s);
•
the amount of common stock involved;
•
the price at which the common stock is to be sold;
•
the commissions paid or the discounts or concessions allowed to the broker dealer(s), where
applicable;
•
that the broker dealer(s) did not conduct any investigation to verify the information set
out or incorporated by reference in the prospectus; and
•
other facts material to the transaction.
The selling stockholders and any underwriters, or broker-dealers or agents that participate in
the distribution of the common stock covered by this prospectus may be deemed to be "underwriters"
within the meaning of Section 2(a)(11) of the Securities Act, and any profit on the sale of the
common stock by them and any discounts, commissions or concessions received by any such
underwriters, dealers or agents may be deemed to be underwriting discounts and commissions under
the Securities Act. Because the selling stockholders may be deemed to be "underwriters" under the
Securities Act, the selling stockholders will be subject to the prospectus delivery requirements of
the Securities Act.
We will not receive any of the proceeds from the sale of the shares covered by this
prospectus. We are paying the expenses incurred in registering the shares of common stock covered
by this prospectus and preparing this prospectus, but all selling and other expenses, including but
not limited to any discounts, commissions and applicable transfer taxes, incurred by each selling
stockholder will be borne by that selling stockholders.
The selling stockholders may agree to indemnify any agent, dealer or broker dealer that
participates in a transaction involving the sale of shares of common stock covered by this
prospectus against certain liabilities, including liabilities arising under the Securities Act.
From time to time, the selling stockholders may pledge their common stock pursuant to the
margin provisions of their customer agreements with their brokers. Upon default by a selling
stockholder,
10
Table of Contents
the broker may offer and sell such pledged common stock from time to time. Upon a sale of the
common stock, the selling stockholders intend to comply with the prospectus delivery requirements
under the Securities Act by delivering a prospectus to each purchaser in the transaction. We intend
to file any amendments or other necessary documents in compliance with the Securities Act that may
be required in the event the selling stockholders default under any customer agreement with
brokers.
We have informed the selling stockholders that the anti manipulative provisions of Regulation
M promulgated under the Exchange Act, may apply to their sales in the market.
In order to comply with the securities laws of certain states, if applicable, the common stock
covered by this prospectus may be sold only through registered or licensed broker-dealers.
The selling stockholders may resell all or a portion of the shares of common stock covered by
this prospectus in open market transactions in reliance upon Rule 144 (as in effect at the time of
sale) under the Securities Act, provided they meet the criteria and conform to the requirements of
such rule. In addition, in accordance with General Instruction C to Form S-8, shares of common
stock to be offered or resold by means of this prospectus by a selling stockholder may not exceed,
during any three month period, the amount specified in Rule 144(e) under the Securities Act.
11
Table of Contents
DISCLOSURE OF SEC'S POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES
Insofar as indemnification for liabilities arising under the Securities Act of 1933, as
amended, may be permitted as to our officers, directors, or persons controlling us, we have been
advised that it is the SEC's opinion that such indemnification is against public policy as
expressed in the Securities Act of 1933, as amended, and is therefore unenforceable.
LEGAL MATTERS
The validity of shares of common stock offered by the selling shareholders named in this
prospectus will be passed upon for us by Akerman Senterfitt, Miami, Florida.
EXPERTS
The financial statements contained in the Annual Report on Form 10-K for the year ended
December 31, 2007 incorporated by reference in this Prospectus have been audited by Grant Thornton
LLP, independent registered public accountants, as indicated in their report with respect thereto,
and is included herein in reliance upon the authority of said firm as experts in accounting and
auditing in giving said report.
12
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The following documents filed with the Securities and Exchange Commission (the "Commission") by
Catalyst Pharmaceutical Partners, Inc. (the "Company") pursuant to the Securities Exchange Act of
1934, as amended (the "Exchange Act"), are incorporated by reference in this Registration
Statement:
1.
The Company's Annual Report on Form 10-K for the year ended December 31, 2007, filed
with the SEC on March 25, 2008;
2.
The Company's Proxy Statement for the 2008 Annual Meeting of Stockholders to be held on
June 18, 2008, filed with the SEC on April 29, 2008;
3.
The Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2008,
filed with the SEC on May 15, 2008;
4.
The Company's description of its common stock contained in its Registration Statement
on Form 8-A, filed with the Commission on September 29, 2006, along with Amendment No. 1
thereto, filed with the Commission on October 18, 2006; and
5.
All documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14
and 15(d) of the Exchange Act, from the date of filing of such documents, before the filing
of a post-effective amendment to this Registration Statement which indicates that all
securities offered hereunder have been sold or which deregisters all securities then
remaining unsold.
Any statement contained in a document incorporated or deemed to be incorporated by reference herein
shall be deemed to be modified or superseded for purposes of this Registration Statement to the
extent that a statement contained herein or in any other subsequently filed document, which also is
incorporated or deemed to be incorporated by reference herein, modifies or supersedes such
statement. Any such statement so modified or superseded shall not be deemed, except as so modified
or superseded, to constitute a part of this Registration Statement.
Item 4. Description of Securities.
The class of securities to be offered is registered under Section 12 of the Securities Exchange Act
of 1934.
Item 5. Interests of Named Experts and Counsel.
The legality of the shares of Common Stock registered hereby has been passed upon for the Company
by Akerman Senterfitt LLP, Miami, Florida. As of the date of this Registration Statement, certain
attorneys employed by Akerman Senterfitt LLP beneficially own shares of the Company's Common Stock.
Item 6. Indemnification of Directors and Officers.
Section 145 of the Delaware General Corporation Law (the "DGCL") provides that a corporation may
indemnify directors and officers as well as other individuals against expenses, judgments, fines
and amounts paid in settlement actually and reasonably incurred by such person in connection with
any
II-1
Table of Contents
threatened, pending or completed actions, suits or proceedings in which such person is made a party
by reason of such person being or having been a director, officer, employee or agent to the
Registrant. The DGCL provides that Section 145 is not exclusive of other rights to which those
seeking indemnification may be entitled under any bylaw, agreement, vote of stockholders or
disinterested directors or otherwise.
Article VII of the Company's Certificate of Incorporation provides that no director of the Company
shall be personally liable to the Company or its stockholders for monetary damages for breach of
fiduciary duty as a director, except for liability (i) for any breach by a director of the duty of
loyalty to the Company or its stockholders, (ii) for acts or omissions not in good faith or which
involve intentional misconduct or a knowing violation of law, (iii) for violations of Section 174
of the DGCL, or (iv) for any transaction from which the director derived an improper personal
benefit.
The Certificate of Incorporation further provides that any amendment of the DGCL that
authorizes corporate action further eliminating or limiting the personal liability of directors,
the liability of a director of the Company shall be eliminated or limited to the fullest extent as
permitted by the DGCL, as amended.
Article VI of the By-Laws of the Company (the "Bylaws") provides that the Company shall indemnify
and hold harmless, to the fullest extent permitted by applicable law as it presently exists or may
hereafter be amended, any person (a "Covered Person") who was or is threatened to be made a party
or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative
or investigative (a "proceeding") by reason of the fact that he or she, or a person for whom he or
she is the legal representative, is or was a director or officer of the Company, is or was serving
at the request of the Company as a director, officer, employee or agent of another corporation or
partnership, joint venture, trust, enterprise or nonprofit entity, including service with respect
to employee benefit plans, against all liability and loss suffered and expenses (including
attorneys' fees) reasonably incurred by such Covered Person. The Company is further required to
indemnify a Covered Person in connection with a proceeding commenced by such Covered Person only if
the commencement of such proceeding by the Covered Person was authorized in the specific case by
the Board of Directors of the Company.
The Bylaws provide that the Company shall, to the fullest extent not prohibited by applicable law,
pay the expenses (including attorneys' fees) incurred by a Covered Person in defending any
proceeding in advance of its final disposition, provided, however, that to the extent required by
law, such payment of expenses in advance of the final disposition of the proceeding shall be made
only upon receipt of an undertaking by the Covered Person to repay all amounts advanced if it is
ultimately determined that the Covered Person is not eligible to be repaid under Article VI of the
Bylaws or otherwise.
The Bylaws provide that if a claim for indemnification (following the final disposition of such
action, suit or proceeding) or advancement of expenses under the Bylaws is not paid in full within
thirty days after a written claim therefor by the Covered Person has been received by the Company,
the Covered Person may file suit to recover the unpaid amount of such claim, and, if successful in
whole or in part, shall be entitled to be paid the expense of prosecuting such claim. In any such
action the Company shall have the burden of proving that the Covered Person is not entitled to the
requested indemnification or advancement of expenses under applicable law.
The Bylaws provide that the rights conferred on any person under Article VI thereof shall not be
exclusive of any other rights which such Covered Person may have or thereafter acquire under any
statute, provision of the Certificate of Incorporation, the Bylaws, agreement, vote of stockholders
or disinterested directors or otherwise.
II-2
Table of Contents
The Bylaws provide that the Company's obligation, if any, to indemnify or to advance expenses to
any Covered Person who was or is serving at its request as a director, officer, employee or agent
of another corporation, partnership, joint venture, trust, enterprise or nonprofit entity shall be
reduced by the amount such Covered Person may collect as indemnification or advancement of expenses
from such other corporation, partnership, joint venture, trust, enterprise or non-profit
enterprise.
The Bylaws provide that any repeal or modification of the provisions of Article VI thereof shall
not adversely affect any right or protection thereunder of any Covered Person in respect of any act
or omission occurring prior to the time of such repeal or modification.
The Bylaws provide that indemnification under Article VI thereof shall not limit the right of the
Company, to the extent and in the manner provided by law, to indemnify and to advance expenses to
persons other than Covered Persons when and as authorized by appropriate corporate action.
Insofar as indemnification for liabilities arising under the Securities Act of 1933, as
amended, is permitted to directors and officers of the Company pursuant to the above statutory
provisions, the Company understands that the Securities and Exchange Commission is of the opinion
that such indemnification contravenes federal public policy as expressed in said act and therefore
is unenforceable.
Item 7. Exemption from Registration Claimed.
Not applicable.
Item 8. Exhibits.
Exhibit No.
Description
4.1
Certificate of Incorporation of Catalyst Pharmaceutical
Partners, Inc. (incorporated by reference to Exhibit 3.1 to
the Company's Registration Statement on Form S-1, filed on
July 25, 2006).
4.2
Certificate of Amendment to the Certificate of Incorporation
of Catalyst Pharmaceutical Partners, Inc. (incorporated by
reference to Exhibit 3.2 of the Company's Registration
Statement on Form S-1, filed on July 25, 2006).
4.3
Bylaws of Catalyst Pharmaceutical Partners, Inc. (incorporated
by reference to Exhibit 3.3 to the Company's Registration
Statement on Form S-1, filed on July 25, 2006).
5.1
Opinion of Akerman Senterfitt.
10.1
Non-Qualified Stock Option
Agreements between the Company and
Patrick J. McEnany (incorporated by reference to Exhibit 10.4
to the Company's Registration Statement on Form S-1, filed on
July 25, 2006).
10.2
Non-Qualified Stock Option
Agreements between the Company and
Hubert E. Huckel, M.D. (incorporated by reference to Exhibit
10.5 to the Company's Registration Statement on Form S-1,
filed on July 25, 2006).
10.3
Non-Qualified Stock Option
Agreements between the Company and
Jack Weinstein (incorporated by reference to Exhibit 10.6 to
the Company's Registration Statement on Form S-1, filed on
July 25, 2006).
10.4
Non-Qualified Stock Option Agreement between the Company and
Charles O'Keeffe (incorporated by reference to Exhibit 10.7 to
the Company's Registration Statement on Form S-1, filed on
July 25, 2006).
II-3
Table of Contents
Exhibit No.
Description
10.5
Non-Qualified Stock Option Agreement between the Company and
M. Douglas Winship (incorporated by reference to Exhibit 10.3
to the Company's Quarterly Report for the Three and Nine
Months Ended September 30, 2006, filed on December 12, 2006)
10.6
Consulting Agreement between the Company and Dr. Donald
Jasinski (incorporated by reference to Exhibit 10.12 to
Amendment No. 1 to the Company's Registration Statement on
Form S-1, filed with the Commission on September 1, 2006)
23.1
Consent of Akerman Senterfitt (Included in Exhibit 5.1).
23.2
Consent of Grant Thornton LLP.
24.1
Power of Attorney (included in the signature pages to this
Registration Statement).
Item 9. Undertakings.
The undersigned registrant hereby undertakes:
1.
To file, during any period in which offers or sales are being made, a post-effective
amendment to this registration statement:
a.
To include any prospectus required by Section 10(a)(3) of the
Securities Act of 1933;
b.
To reflect in the prospectus any facts or events arising after the
effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental
change in the information set forth in the registration statement. Notwithstanding
the foregoing, any increase or decrease in volume of securities offered (if the
total dollar value of securities offered would not exceed that which was
registered) and any deviation from the low or high end of the estimated maximum
offering range may be reflected in the form of prospectus filed with the Commission
pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price
represent no more than 20% change in the maximum aggregate offering price set forth
in the "Calculation of Registration Fee" table in the effective registration
statement.
c.
To include any material information with respect to the plan of
distribution not previously disclosed in the registration statement or any material
change to such information in the registration statement;
Provided however, that paragraphs (a)(1)(a) and (a)(1)(b) above do not apply if the
information required to be included in a post-effective amendment by those paragraphs is
contained in reports filed with or furnished to the Commission by the registrant pursuant to
section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by
reference in the registration statement.
2.
That, for the purpose of determining any liability under the Securities Act of 1933,
each such post-effective amendment shall be deemed to be a new registration statement
relating to the
II-4
Table of Contents
securities offered therein, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof.
3.
To remove from registration by means of a post-effective amendment any of the
securities being registered which remain unsold at the termination of the offering.
4.
The undersigned registrant hereby undertakes that, for purposes of determining any
liability under the Securities Act of 1933, each filing of the registrant's annual report
pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and,
where applicable, each filing of an employee benefit plan's annual report pursuant to
section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in
the registration statement shall be deemed to be a new registration statement relating to
the securities offered therein, and the offering of such securities at that time shall be
deemed to be the initial bona fide offering thereof.
5.
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be
permitted to directors, officers and controlling persons of the registrant pursuant to the
foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the
Securities and Exchange Commission such indemnification is against public policy as expressed in
the Act and is, therefore, unenforceable. In the event that a claim for indemnification against
such liabilities (other than the payment by the registrant of expenses incurred or paid by a
director, officer or controlling person of the registrant in the successful defense of any action,
suit or proceeding) is asserted by such director, officer or controlling person in connection with
the securities being registered, the registrant will, unless in the opinion of its counsel the
matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Act and
will be governed by the final adjudication of such issue.
II-5
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, Catalyst Pharmaceutical
Partners, Inc. certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-8 and has duly caused this Registration Statement on Form S-8 to
be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Coral Gables,
State of Florida, on June 2, 2008.
CATALYST PHARMACEUTICAL
PARTNERS, INC.
By:
/s/ Patrick J. McEnany
Patrick J. McEnany, Chairman,
President and CEO
POWER OF ATTORNEY
Each person whose signature appears below hereby constitutes and appoints Patrick J. McEnany
and Jack Weinstein, and each of them, as his true and lawful attorneys-in-fact and agents, with
full power of substitution and resubstitution for him and in his name, place, and stead, in any and
all capacities, to sign any or all amendments or supplements to this registration statement,
whether pre-effective or post-effective, including any subsequent registration statement for the
same offering which may be filed under Rule 462(b) under the Securities Act of 1933, as amended, to
file the same with all exhibits thereto and other documents in connection therewith, with the
Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of
them, full power and authority to do and perform each and every act and thing necessary or
appropriate to be done with respect to this registration statement or any amendments or supplements
hereto in the premises, as fully to all intents and purposes as he might or could do in person,
hereby ratifying and confirming that all said attorneys-in-fact and agents, or any of them, or this
or his substitute or substitutes, may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Act of 1933, this report has been signed by the
following persons, in the capacities and on the dates indicated.
Signature
Title
Date
/s/ Patrick J. McEnany
Patrick J. McEnany
Chairman of the Board
of
Directors,
President and Chief
Executive Officer
June 2, 2008
/s/ Jack Weinstein
Jack Weinstein
Vice President, Treasurer
and
Chief
Financial Officer
June 2, 2008
/s/ Alicia Grande
Alicia Grande
Corporate Controller/Chief
Accounting Officer
June 2, 2008
/s/ Hubert E. Huckel, M.D.
Hubert E. Huckel, M.D.
Director
June 2, 2008
/s/ Charles B. O'Keeffe
Charles B. O'Keeffe
Director
June 2, 2008
Table of Contents
Signature
Title
Date
/s/ Philip H. Coelho
Philip H. Coelho
Director
June 2, 2008
/s/ David S. Tierney, M.D.
David S. Tierney, M.D.
Director
June 2, 2008
/s/ Milton J. Wallace
Milton J. Wallace
Director
June 2, 2008